Clinical Trial Update: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on safety and bioactivity of AXT107 in neovascular age-related macular degeneration; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• AXT107

Snippet

Sponsor: AsclepiX Therapeutics, Inc. | Conditions: Neovascular Age-Related Macular Degeneration (nAMD) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-03-22